Vitamin D: Production, Metabolism, Mechanism of Action, and Clinical Requirements

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition

Volumn , Issue , 2013, Pages 235-247

  Bikle, Daniel ^a   Adams, John S ^b   Christakos, Sylvia ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Classical target tissues; Clinical requirements; Keratinocyte function; Metabolism; Metabolites; Nonclassical target tissues; Nutritional considerations; Vitamin D

Indexed keywords

EID: 85009848202     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118453926.ch29     Document Type: Chapter

References (95)

1. Holick MF, McLaughlin JA, Clark MB, Doppelt SH. 1981. Factors that influence the cutaneous photosynthesis of previtamin D3. Science 211: 590-593.
2. Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT Jr, Anderson RR, Blank IH, Parrish JA, Elias P. 1980. Photosynthesis of previtamin D3 in human and the physiologic consequences. Science 210: 203-205.
3. Holick MF, Richtand NM, McNeill SC, Holick SA, Frommer JE, Henley JW, Potts JT Jr. 1979. Isolation and identification of previtamin D3 from the skin of exposed to ultraviolet irradiation. Biochemistry 18: 1003-1008.
4. Webb AR, Kline L, Holick MF. 1988. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67: 373-378.
5. Adams JS, Clemens TL, Parrish JA, Holick MF. 1982. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med 306: 722-725.
6. Heaney RP, Horst RL, Cullen DM, Armas LA. 2009. Vitamin D3 distribution and status in the body. J Am Coll Nutr 28: 252-256.
7. Holick MF. 2007. Vitamin D deficiency. N Engl J Med 357: 266-281.
8. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS. 2007. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 103: 316-321.
9. Zierold C, Darwish HM, DeLuca HF. 1995. Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J Biol Chem 270: 1675-1678.
10. Ren S, Nguyen L, Wu S, Encinas C, Adams JS, Hewison M. 2005. Alternative splicing of vitamin D-24-hydroxylase: A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem 280: 20604-20611.
11. Wu S, Ren S, Nguyen L, Adams JS, Hewison M. 2007. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology 148: 3410-3418.
12. Bikle DD, Pillai S, Gee E, Hincenbergs M. 1989. Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 124: 655-660.
13. Bikle DD, Pillai S, Gee E, Hincenbergs M. 1991. Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology 129: 33-38.
14. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zugel U, Bikle DD, Modlin RL, Gallo RL. 2007. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117: 803-811.
15. Cooke NE, Haddad JG. 1989. Vitamin D binding protein (Gc-globulin). Endocr Rev 10: 294-307.
16. Liang C, Cooke N. 2005. Vitamin D-binding protein. In: Feldman D, Pike JW, Glorieux F (eds.) Vitamin D, 2nd Ed. San Diego: Elsevier Academic Press. pp. 117-134.
17. Willnow T, Nykjaer A. 2005. Endocytic pathways for 25-(OH) vitamin D3. In: Feldman D, Pike JW, Glorieux F (eds.) Vitamin D, 2nd Ed. San Diego: Elsevier Academic Press. pp. 153-163.
18. Zella LA, Shevde NK, Hollis BW, Cooke NE, Pike JW. 2008. Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 149: 3656-3667.
19. Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, Liebhaber SA, Cooke NE. 1999. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 103: 239-251.
20. Adams JS. 2005. "Bound" to work: The free hormone hypothesis revisited. Cell 122: 647-649.
21. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. 2003. New insights into the mechanisms of vitamin D action. J Cell Biochem 88: 695-705.
22. DeLuca HF. 2004. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80: 1689S-1696S.
23. Rachez C, Freedman LP. 2000. Mechanisms of gene regulation by vitamin D(3) receptor: A network of coactivator interactions. Gene 246: 9-21.
24. Sutton AL, MacDonald PN. 2003. Vitamin D: More than a "bone-a-fide" hormone. Mol Endocrinol 17: 777-791.
25. Christakos S, Dhawan P, Benn BS, Porta A, Hediger M, Oh GT, Jeung EB, Zhong Y, Ajibade D, Dhawan K, Joshi S. 2007. Vitamin D: Molecular mechanism of action. Ann NY Acad Sci 1116: 340-348.
26. Christakos S, Dhawan P, Peng X, Obukhov AG, Nowycky MC, Benn BS, Zhong Y, Liu Y, Shen Q. 2007. New insights into the function and regulation of vitamin D target proteins. J Steroid Biochem Mol Biol 103: 405-410.
27. Dhawan P, Peng X, Sutton AL, MacDonald PN, Croniger CM, Trautwein C, Centrella M, McCarthy TL, Christakos S. 2005. Functional cooperation between CCAAT/enhancer-binding proteins and the vitamin D receptor in regulation of 25-hydroxyvitamin D3 24-hydroxylase. Mol Cell Biol 25: 472-487.
28. Guo B, Aslam F, van Wijnen AJ, Roberts SG, Frenkel B, Green MR, DeLuca H, Lian JB, Stein GS, Stein JL. 1997. YY1 regulates vitamin D receptor/retinoid X receptor mediated transactivation of the vitamin D responsive osteocalcin gene. Proc Natl Acad Sci U S A 94: 121-126.
29. Raval-Pandya M, Dhawan P, Barletta F, Christakos S. 2001. YY1 represses vitamin D receptor-mediated 25-hydroxyvitamin D(3)24-hydroxylase transcription: Relief of repression by CREB-binding protein. Mol Endocrinol 15: 1035-1046.
30. Christakos S, Dhawan P, Shen Q, Peng X, Benn B, Zhong Y. 2006. New insights into the mechanisms involved in the pleiotropic actions of 1,25dihydroxyvitamin D3. Ann N Y Acad Sci 1068: 194-203.
31. Pike JW, Meyer MB. 2010. The vitamin D receptor: New paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 39: 255-269.
32. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y. 2007. alpha-Klotho as a regulator of calcium homeostasis. Science 316: 1615-1618.
33. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB. 1997. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 94: 9831-9835.
34. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16: 391-396.
35. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB. 1999. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 140: 4982-4987.
36. Xue Y, Fleet JC. 2009. Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology 136: 1317-1327, e1311-1312.
37. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D. 2004. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 279: 16754-16766.
38. Raisz LG, Trummel CL, Holick MF, DeLuca HF. 1972. 1,25-dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 175: 768-769.
39. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597-3602.
40. Prince CW, Butler WT. 1987. 1,25-Dihydroxyvitamin D3 regulates the biosynthesis of osteopontin, a bonederived cell attachment protein, in clonal osteoblastlike osteosarcoma cells. Coll Relat Res 7: 305-313.
41. Price PA, Baukol SA. 1980. 1,25-Dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. J Biol Chem 255: 11660-11663.
42. Drissi H, Pouliot A, Koolloos C, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 2002. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274: 323-333.
43. Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, White CP, Sunn KL, Morrison NA, Walsh WR, Eisman JA. 2000. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 14: 1908-1916.
44. Raval-Pandya M, Porta A, Christakos S. 1998. Mechanism of action of 1,25 dihydroxyvitamin D3 on intestinal calcium absorption and renal calcium transportation. In: Holick MF (ed.) Vitamin D Physiology, Molecular Biology and Clinical Applications. Totowa, NJ: Humana Press. pp. 163-173.
45. Wasserman RH, Fullmer CS. 1995. Vitamin D and intestinal calcium transport: Facts, speculations and hypotheses. J Nutr 125: 1971S-1979S.
46. Fleet JC, Schoch RD. 2010. Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Crit Rev Clin Lab Sci 47: 181-195.
47. Akhter S, Kutuzova GD, Christakos S, DeLuca HF. 2007. Calbindin D9k is not required for 1,25-dihydroxyvitamin D3-mediated Ca2 + absorption in small intestine. Arch Biochem Biophys 460: 227-232.
48. Kutuzova GD, Akhter S, Christakos S, Vanhooke J, Kimmel-Jehan C, Deluca HF. 2006. Calbindin D(9k) knockout mice are indistinguishable from wild-type mice in phenotype and serum calcium level. Proc Natl Acad Sci U S A 103: 12377-12381.
49. Hoenderop JG, Nilius B, Bindels RJ. 2003. Epithelial calcium channels: From identification to function and regulation. Pflugers Arch 446: 304-308.
50. Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM, Hediger MA. 1999. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem 274: 22739-22746.
51. Benn BS, Ajibade D, Porta A, Dhawan P, Hediger M, Peng JB, Jiang Y, Oh GT, Jeung EB, Lieben L, Bouillon R, Carmeliet G, Christakos S. 2008. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 149: 3196-3205.
52. Williams KB, DeLuca HF. 2007. Characterization of intestinal phosphate absorption using a novel in vivo method. Am J Physiol Endocrinol Metab 292: E1917-1921.
53. Sabbagh Y, O ' Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, Schiavi SC. 2009. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20: 2348-2358.
54. Sneddon WB, Barry EL, Coutermarsh BA, Gesek FA, Liu F, Friedman PA. 1998. Regulation of renal parathyroid hormone receptor expression by 1, 25-dihydroxyvitamin D3 and retinoic acid. Cell Physiol Biochem 8: 261-277.
55. Lambers TT, Weidema AF, Nilius B, Hoenderop JG, Bindels RJ. 2004. Regulation of the mouse epithelial Ca2(+) channel TRPV6 by the Ca(2 +)-sensor calmodulin. J Biol Chem 279: 28855-28861.
56. Omdahl JL, Bobrovnikova EA, Choe S, Dwivedi PP, May BK. 2001. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids 66: 381-389.
57. Kaneko I, Segawa H, Furutani J, Kuwahara S, Aranami F, Hanabusa E, Tominaga R, Giral H, Caldas Y, Levi M, Kato S, Miyamoto K. 2011. Hypophosphatemia in vitamin D receptor null mice: Effect of rescue diet on the developmental changes in renal Na +-dependent phosphate cotransporters. Pflugers Arch J Physiol 461: 77-90.
58. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. 1992. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 89: 8097-8101.
59. Martin KJ, Gonzalez EA. 2004. Vitamin D analogs: Actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 24: 456-459.
60. Canaff L, Hendy GN. 2002. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 277: 30337-30350.
61. Christakos S, Norman AW. 1979. Studies on the mode of action of calciferol. XVIII. Evidence for a specific high affinity binding protein for 1,25 dihydroxyvitamin D3 in chick kidney and pancreas. Biochem Biophys Res Commun 89: 56-63.
62. Clark SA, Stumpf WE, Sar M, DeLuca HF, Tanaka Y. 1980. Target cells for 1,25 dihydroxyvitamin D3 in the pancreas. Cell Tissue Res 209: 515-520.
63. Morrissey RL, Bucci TJ, Richard B, Empson N, Lufkin EG. 1975. Calcium-binding protein: Its cellular localization in jejunum, kidney and pancreas. Proc Soc Exp Biol Med 149: 56-60.
64. Sooy K, Schermerhorn T, Noda M, Surana M, Rhoten WB, Meyer M, Fleischer N, Sharp GW, Christakos S. 1999. Calbindin-D(28k) controls [Ca(2 +)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines. J Biol Chem 274: 34343-34349.
65. Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S. 2001. Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokineinduced apoptosis and necrosis. Endocrinology 142: 3649-3655.
66. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1983. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221: 1181-1183.
67. Adams JS, Sharma OP, Gacad MA, Singer FR. 1983. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 72: 1856-1860.
68. Rook GA, Steele J, Fraher L, Barker S, Karmali R, O ' Riordan J, Stanford J. 1986. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57: 159-163.
69. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH. 2004. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173: 2909-2912.
70. Gombart AF, Borregaard N, Koeffler HP. 2005. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19: 1067-1077.
71. Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Torma H, Stahle M. 2005. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 124: 1080-1082.
72. Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449: 819-826.
73. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
74. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, Modlin RL, Hewison M. 2009. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 182: 4289-4295.
75. Hewison M. 2011. Antibacterial effects of vitamin D. Nat Rev Endocrinol 7: 337-345.
76. Kreutz M, Andreesen R, Krause SW, Szabo A, Ritz E, Reichel H. 1993. 1,25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 82: 1300-1307.
77. Bruce D, Ooi JH, Yu S, Cantorna MT. 2010. Vitamin D and host resistance to infection? Putting the cart in front of the horse. Exp Biol Med (Maywood) 235: 921-927.
78. Penna G, Adorini L. 2000. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164: 2405-2411.
79. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, Adorini L. 2007. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178: 145-153.
80. Bikle DD, Nemanic MK, Whitney JO, Elias PW. 1986. Neonatal human foreskin keratinocytes produce 1,25-dihydroxyvitamin D3. Biochemistry 25: 1545-1548.
81. Su MJ, Bikle DD, Mancianti ML, Pillai S. 1994. 1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. J Biol Chem 269: 14723-14729.
82. Hawker NP, Pennypacker SD, Chang SM, Bikle DD. 2007. Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J Invest Dermatol 127: 874.
83. Malloy PJ, Pike JW, Feldman D. 1999. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 20: 156-188.
84. Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. 2005. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol 19: 855-862.
85. Bikle DD, Elalieh H, Chang S, Xie Z, Sundberg JP. 2006. Development and progression of alopecia in the vitamin D receptor null mouse. J Cell Physiol 207: 340-353.
86. Cianferotti L, Cox M, Skorija K, Demay MB. 2007. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc Natl Acad Sci U S A 104: 9428-9433.
87. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. 2011. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96: 53-58.
88. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. 2005. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293: 2257-2264.
89. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. 1992. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327: 1637-1642.
90. Ponsonby AL, McMichael A, van der Mei I. 2002. Ultraviolet radiation and autoimmune disease: Insights from epidemiological research. Toxicology 181-182: 71-78.
91. Boscoe FP, Schymura MJ. 2006. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 6: 264.
92. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. 2007. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 85: 1586-1591.
93. Vieth R. 1999. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69: 842-856.
94. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. 2003. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77: 204-210.
95. Hathcock JN, Shao A, Vieth R, Heaney R. 2007. Risk assessment for vitamin D. Am J Clin Nutr 85: 6-18.